Aligos Therapeutics (ALGS) News Today $10.91 -0.15 (-1.36%) As of 10:06 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALGS Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Brokers Set Expectations for ALGS Q3 EarningsAugust 22, 2025 | marketbeat.comEquities Analysts Set Expectations for ALGS Q3 EarningsAugust 22, 2025 | americanbankingnews.comAligos Therapeutics appoints Ramon Polo as head of global regulatory affairsAugust 20, 2025 | msn.comAligos Therapeutics Appoints Ramón Polo as Senior VP, Head of Global Regulatory AffairsAugust 20, 2025 | quiverquant.comQAligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory AffairsAugust 20, 2025 | globenewswire.comAligos Therapeutics (NASDAQ:ALGS) Coverage Initiated at HC WainwrightAugust 20, 2025 | americanbankingnews.comAligos Therapeutics assumed with a Buy at H.C. WainwrightAugust 18, 2025 | msn.comAligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 15, 2025 | globenewswire.comAligos Therapeutics announces first subject dosed in Phase 2 B-SUPREME studyAugust 14, 2025 | msn.comAligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV InfectionAugust 13, 2025 | globenewswire.comAligos Therapeutics reports Q2 EPS ($1.53), consensus ($2.54)August 7, 2025 | msn.comAligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial ResultsAugust 6, 2025 | globenewswire.comAligos Therapeutics (NASDAQ:ALGS) Will Have To Spend Its Cash WiselyJuly 31, 2025 | finance.yahoo.comAligos Therapeutics, Inc. to Announce Second Quarter 2025 Financial Results on August 6, 2025July 30, 2025 | quiverquant.comQAligos Therapeutics to Announce 2nd Quarter 2025 Financial Results on August 6, 2025July 30, 2025 | globenewswire.comAligos Therapeutics (ALGS) Projected to Post Quarterly Earnings on TuesdayJuly 29, 2025 | marketbeat.comAligos Therapeutics (NASDAQ:ALGS) Shares Up 1.8% - Time to Buy?July 24, 2025 | marketbeat.comReadystate Asset Management LP Acquires New Stake in Aligos Therapeutics, Inc. (NASDAQ:ALGS)July 24, 2025 | marketbeat.comAligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 11, 2025 | globenewswire.comAligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC)June 18, 2025 | globenewswire.comAligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 13, 2025 | globenewswire.comAligos Therapeutics to Present at the Jefferies Global Healthcare ConferenceMay 29, 2025 | globenewswire.comAligos Stock Price HistoryMay 26, 2025 | investing.comAligos Therapeutics Appoints Laura Kavanaugh as Vice President, Head of LegalMay 20, 2025 | globenewswire.comAligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 16, 2025 | globenewswire.comAligos Therapeutics Presents Positive Data at the EASL Congress 2025May 8, 2025 | globenewswire.comAligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial ResultsMay 6, 2025 | globenewswire.com4ALGS : Aligos Therapeutics's Earnings OutlookMay 6, 2025 | benzinga.comAligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025April 29, 2025 | globenewswire.comAligos Therapeutics Announces Eight Abstracts Accepted for Presentation at the EASL Congress 2025April 23, 2025 | globenewswire.comAligos Therapeutics' (ALGS) "Buy" Rating Reiterated at HC WainwrightApril 1, 2025 | marketbeat.comAligos Therapeutics files to sell 6.25M shares of common stock for holdersMarch 29, 2025 | markets.businessinsider.comA Path to a Healthier Future With Chronic Hepatitis B Virus InfectionMarch 28, 2025 | usatoday.comAligos Therapeutics presents positive data at APASL2025March 27, 2025 | markets.businessinsider.comAligos Therapeutics Presents Positive Data at APASL 2025March 26, 2025 | globenewswire.comTen option delistings on March 24thMarch 24, 2025 | markets.businessinsider.com30,570 Shares in Aligos Therapeutics, Inc. (NASDAQ:ALGS) Purchased by Avantax Advisory Services Inc.March 19, 2025 | marketbeat.comAligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 14, 2025 | globenewswire.comAligos Therapeutics Faces Challenges in Developing Hepatitis B Treatments Amidst Industry CompetitionMarch 12, 2025 | tipranks.comAligos Therapeutics price target lowered to $70 from $75 at H.C. WainwrightMarch 11, 2025 | markets.businessinsider.comAligos Therapeutics reports Q4 EPS ($13.08) vs ($5.50) last yearMarch 10, 2025 | markets.businessinsider.comAligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial ResultsMarch 10, 2025 | globenewswire.comAligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Up 23.7% in FebruaryMarch 5, 2025 | marketbeat.comAligos Therapeutics (ALGS) to Release Earnings on TuesdayMarch 4, 2025 | marketbeat.comAligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025March 3, 2025 | globenewswire.comAligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Large Decrease in Short InterestFebruary 17, 2025 | marketbeat.comAligos Therapeutics announces $105M private placement financingFebruary 12, 2025 | markets.businessinsider.comAligos Therapeutics secures $105 million in private placementFebruary 12, 2025 | msn.comAligos Therapeutics Announces $105 Million Private Placement FinancingFebruary 12, 2025 | globenewswire.comHere's Why Aligos Therapeutics (NASDAQ:ALGS) Must Use Its Cash WiselyFebruary 8, 2025 | finance.yahoo.com Get Aligos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALGS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALGS Media Mentions By Week ALGS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALGS News Sentiment▼1.301.03▲Average Medical News Sentiment ALGS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALGS Articles This Week▼22▲ALGS Articles Average Week Get the Latest News and Ratings for ALGS and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Aligos Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Humacyte News Today SOPHiA GENETICS News Today Adherex Technologies News Today Tiziana Life Sciences News Today Aerovate Therapeutics News Today ProQR Therapeutics News Today Entrada Therapeutics News Today Sagimet Biosciences News Today enGene News Today GENFIT News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALGS) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aligos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aligos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access